Effects of trimetazidine in patients with severe chronic heart failure with reduced left ventricular ejection fraction: A prospective, randomized, open-label, cross-over study by Bohdan, Michał et al.
Address for correspondence: Michał Bohdan, MD, PhD, First Department of Cardiology, Medical University of Gdansk,  
ul. Dębinki 7, 80–952 Gdansk, Poland, tel: +48 58 349 25 00, fax: +48 58 349 12 01, e-mail: michal.bohdan@gumed.edu.pl
Received: 20.09.2019 Accepted: 13.10.2020 Early publication date: 9.11.2020
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Effects of trimetazidine in patients with severe 
chronic heart failure with reduced left ventricular 
ejection fraction: A prospective, randomized,  
open-label, cross-over study
Michał Bohdan1, Iwona Stopczyńska1, Piotr Wiśniewski2,  
Joanna Moryś3, Piotr Niedoszytko4, Marcin Gruchała1
1First Department of Cardiology, Medical University of Gdansk, Poland 
2Department of Endocrinology and Internal Diseases, Medical University of Gdansk, Poland 
3Department of Clinical Psychology, Medical University of Gdansk, Poland 
4Department of Rehabilitation Medicine, Medical University of Gdansk, Poland
Abstract
Background: Trimetazidine (TMZ) modulates cardiac metabolism, but its use in heart failure re-
mains controversial. The aim of the study was to evaluate the effects of TMZ on exercise capacity, left 
ventricular ejection fraction (LVEF), mortality, and quality of life in stable patients with heart failure 
with reduced left ventricular ejection fraction (HFrEF).
Methods: Forty-five patients with stable advanced HFrEF treated with optimal medical therapy were 
randomized in a prospective, single-center, open-label, cross-over study of TMZ (35 mg b.i.d.) on top of 
standard medical therapy or standard pharmacotherapy for two periods of 30 days and one period of 
6 months. Initially and at the end of each period all patients underwent the following: exercise testing, 
six-minute walk test (6MWT), two-dimensional-echocardiography, and quality of life assessment. 
Results: The mean age of patients was 58.2 ± 10.6 years. Etiology of HFrEF was ischemic in 66.6% 
of patients. After 6 months no significant changes were observed in either group with regards to peak 
VO2 uptake, 6MWT, LVEF, or quality of life. TMZ had no effect on mortality or cardiovascular events. 
Conclusions: The additional use of TMZ on top of standard medical therapy in stable advanced 
HFrEF patients was not associated with significant changes in mortality, exercise capacity, LVEF, or 
quality of life. (Cardiol J)
Key words: trimetazidine, heart failure, cardiac metabolism, exercise capacity,  
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Introduction
Chronic heart failure (CHF) is one of the major 
challenges for healthcare systems in developed 
countries. Recently, the prevalence of CHF has 
increased from 5.7 to 6.5 million in Americans 
aged ≥ 20 years [1]. Despite improvements in CHF 
therapy, the prognosis is poor, with 5-year survival 
reaching 61% in patients with CHF after myocar-
dial infarction [2]. It has been shown that CHF is 
a syndrome characterized by metabolic abnormali-
ties in the myocardium that lead to energy starva-
tion [3]. Progression of heart failure is associated 
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and promotion of glucose oxidation [3]. Metabolic 
alterations that occur in CHF mandate the potential 
use of metabolic modulators. 
Trimetazidine (TMZ) has been evaluated in 
randomized trials and several meta-analyses in 
CHF patients. It has been observed that TMZ on 
top of standard pharmacotherapy reduces morbidity 
and mortality in patients with chronic heart failure 
with reduced left ventricular ejection fraction 
(HFrEF) [4–8]. Moreover, some studies suggest 
that TMZ may reduce the symptoms in New York 
Heart Association (NYHA) classification and in-
crease the exercise duration in CHF [9, 10]. Some 
studies also indicate that TMZ may improve car-
diopulmonary stress testing results and six-minute 
walk test (6MWT) distance [11, 12]. 
The available results of TMZ in CHF patients 
were derived mainly from retrospective analyses 
and small studies. There has been only one study 
assessing the effects of TMZ on cardiopulmonary 
stress testing and echocardiography in patients 
with nonischemic CHF [13]. Moreover, the data 
on beneficial role of TMZ in CHF are conflicting 
[13]. There are insufficient data from prospective 
analyses to support the use of TMZ in HFrEF. The 
aim of the study was to evaluate the effects of TMZ 
on exercise capacity, left ventricular ejection frac-
tion (LVEF), cardiovascular mortality, and quality 
of life in CHF patients. 
Methods
Patients were randomized to TMZ (35 mg 
b.i.d.) on top of medical therapy for 1 month fol-
lowed by medical therapy alone for another month 
and then TMZ for 6 months (Group 1) and to 
medical therapy for 1 month followed by additional 
TMZ for another month and then medical therapy 
without TMZ for 6 months (Group 2) according 
to a computer-generated random list (Fig. 1) (Re-
search randomizer, https://www.randomizer.org/). 
A wash-out period of 1 month was chosen to avoid 
any potential effect of TMZ on heart function after 
TMZ cessation. The primary endpoint of the study 
was change in mean LVEF. Secondary endpoints 
included changes in exercise capacity and quality of 
life. Inclusion criteria were as follows: 1) ischemic 
or nonischemic CHF for at least 1 year prior to 
randomization; 2) LVEF ≤ 35% evaluated in two-
-dimensional (2D) echocardiography at the index 
visit; 3) at least one documented CHF exacerbation 
within 12 months prior to randomization; 4) stable 
course of CHF with NYHA class II or III, defined as 
no exacerbation of CHF symptoms and/or no modi-
fications of treatment for at least 3 months prior to 
randomization; and 5) age ≥ 18 years. Exclusion cri-
teria were as follows: 1) primary valvular disease; 
2) neurological disorders; 3) severe kidney disease, 
with estimated glomerular filtration rate (eGFR) 
< 30 mL/kg/min; 4) frailty syndrome; 5) presence 
of coronary lesions suitable for revascularization; 
6) alcohol abuse; and 7) pregnancy.  
Initially and during each visit cardiopulmonary 
stress testing (Medisoft Ergocard, Belgium) and 
6MWT were performed in all patients. Symptom 
severity was assessed with the use of NYHA 
classification. LVEF was calculated automati-
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Figure 1. Study design. Standard pharmacotherapy = beta-blocker and angiotensin converting enzyme inhibitor or 
angiotensin receptor blocker and aldosterone blocker, if not contraindicated; TMZ — trimetazidine.
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echocardiography (Vivid 6, GE Healthcare, USA). 
The MacNew heart disease health-related qual-
ity of life questionnaire was used to measure 
quality of life. Blood samples were also taken for 
further analyses. Adverse events associated with 
TMZ were monitored by a safety committee. The 
study was approved by Local Ethics Committee 
(NKBBN/346/2012).
Statistical analysis
Continuous variables are presented as mean 
± standard deviation and categoric variables as 
percentages (%). All statistical analyses were 
performed with STATA, version 13.1 (Statacorp, 
Texas, USA). Baseline parameters in two groups 
were compared by two-sample t-test or Mann-
-Whitney test. In order to assess the effects of 
TMZ in the study group mixed models with random 
effects analysis was applied. To investigate the pos-
sible treatment, carry-over, sequence, and period 
effects, the ‘pkcross’ function in STATA software 
was used. 
The results of the analyses are presented as 
changes in values of specific parameters at various 
time points in both groups. 
In order to evaluate the impact of TMZ on 
survival a Kaplan-Meier estimator and log-rank 
test to make comparisons between groups were 
applied. The effect of TMZ on survival and cardio-
vascular (CV) risk (CV hospitalization, implant-
able cardioverter-defibrillator [ICD] appropriate 
intervention(s), CV death) was assessed using 
a discreet-time hazard model. The significance 
level was set at p ≤ 0.05.
Power calculation was based on a paired t-test 
assuming a two-sided level of significance a = 0.05, 
power 1-b = 0.80. For the effect size calculation 
we assumed an expected mean LVEF change of 5% 
and a standard deviation of 8% in changes in LVEF 
from baseline to 6 months after treatment with the 
required sample size of n = 20. To compensate for 
potential drop-out, we increased the total number 
of patients for this study to n = 45.
Results
Forty-five patients with HFrEF were re-
cruited in a prospective, single-center, open-label, 
cross-over study. All patients received standard 
pharmacotherapy for at least 6 months prior to ran-
domization with b-blocker, angiotensin-converting 
enzyme inhibitor (ACEI) or angiotensin II receptor 
blocker (ARB), aldosteron blocker and diuretics, di-
goxin, and ivabradine were indicated. The mean age 
of study group was 58.2 ± 10.6 years. The majority 
of patients were male (n = 43, 95.6%). There were 
no significant differences in basal characteristics 
in both groups except creatinine level (Table 1). 
Visits number 2, 3, and 4 were completed by 95.3%, 
86.7%, and 73.3% of patients, respectively. Five 
patients were lost to follow-up. One patient was 
diagnosed with intracranial aneurysm and was 
referred to surgery, while 3 patients had CHF ex-
acerbation and were not able to complete visit 4. 
Three patients died due to CV reasons, and 
19 patients had 22 CV events (hospitalizations 
due to CV reasons, ICD intervention due to ven-
tricular tachycardia). One patient experienced 
gastro-intestinal side effects that were attributed 
to TMZ. 
Exercise capacity
Additional use of TMZ had no effect on peak 
oxygen consumption (VO2 peak) and VO2 at the 
anaerobic threshold in both groups (Fig. 2A, B). 
Reduction of slope of minute ventilation versus 
carbon dioxide production (VE/VCO2 slope) after 
1-month treatment with TMZ in Group 1 was 
observed (47.2 ± 2.4 vs. 40.9 ± 2.5 at 1 month, 
p = 0.07; Fig. 2C). No effect of TMZ on 6MWT 
distance was noted in either group (Fig. 2D). There 
was a significant reduction in NYHA classification 
at visit 2 in Group 2, and a similar tendency was ob-
served in Group 1 at visit 3 (2.4 ± 0.1 vs. 2.0 ± 0.1, 
p < 0.01 and 2.4 ± 0.1 vs. 2.1 ± 0.1, respec-
tively). In addition, patients in Group 2 at visit 4 
experienced a significant increase in symptom 
severity in NYHA class (2.1 ± 0.1 vs. 2.4 ± 0.1, 
p < 0.05; Fig. 3D). 
Echocardiography
Patients in Group 1 at visit 4 had a tendency to-
wards LVEF increase (24.6 ± 1.4% vs. 26.7 ± 1.5%, 
p = 0.059). Moreover, no significant effect of TMZ 
on left ventricular end-diastolic diameter (LVEDD) 
and left ventricular end-systolic diameter (LVESD) 
was found. Patients from Group 2 at visit 2 had 
significant increase in LVESD (60.0 ± 1.8 mm vs. 
64.7±1.9 mm, p < 0.05). Interestingly, this effect 
in Group 2 was not confirmed during the following 
6 months of observation on standard pharmaco-
therapy alone (Fig. 3A–C). 
Laboratory evaluation
There were no differences in B-type natriu-
retic peptide (BNP) level at various time points in 
both groups. A significant rise in C-reactive protein 
(CRP) level was observed in patients in Group 1 
www.cardiologyjournal.org 3
Michał Bohdan et al., Trimetazidine in chronic heart failure
Table 1. Baseline characteristics.
Group I (n = 22) Group II (n = 23) P
Age [years] 59 ± 9.6 57.3 ± 11.6 NS
Gender, male 22 (48.9%) 21 (46.7%) NS
CHF duration [years] 3.5 ± 3.13 3.17 ± 1.72 NS
CHF etiology:
Ischemic 15 (33.3%) 15 (33.3%) NS
Nonischemic 7 (15.6%) 8 (17.8%) NS
Concomitant diseases:
Diabetes 3 (6.7%) 8 (17.8%) NS
Hypertension 11 (24.4%) 12 (26.7%) NS
Chronic kidney disease 8 (18.2%) 6 (13.6%) NS
COPD 3 (6.8%) 2 (4.6%) NS
CRT 7 (15.9%) 3 (6.8%) NS
NYHA (mean ± SD) 2.3 ± 0.5 2.4 ± 0.5 NS
NYHA II 16 (35.6%) 13 (28.9%) NS
NYHA III 6 (13.3%) 10 (22.2%) NS
BMI [kg/m2] 27.5 ± 5.1 28.8 ± 3.7 NS
BNP [pg/mL] 694.2 ± 746.8 575.0 ± 502.5 NS
Hemoglobin [g/L] 13.9 ± 1.5 14.5 ± 1.5 NS
Red cell width 15.1 ± 1.7 15.3 ± 2.1 NS
Sodium [mmol/L] 138.5 ± 2.4 137.3 ± 3.2 NS
hs-CRP [mg/L] 2.9 ± 1.9 3.2 ± 2.5 NS
Creatinine [mg/dL] 1.3 ± 0.3 1.1 ± 0.2 < 0.05
eGFR [mL/kg/1.73 m2] 63.6 ± 18.7 72.3 ± 16.5 NS
Sinus rhythm 10 (24.4%) 16 (39%) NS
LVEF [%] 23.6 ± 5.9 22.5 ± 6.7 NS
VO2 peak [mL/kg/min] 11.7 ± 3.7 12.3 ± 3.9 NS
VO2 (AT) [mL/kg/min] 8.8 ± 2.6 9.2 ± 1.9 NS
VE/VCO2 slope 46.7 ± 12.9 40.5 ± 10.9 NS
6MWT (m) 392.7 ± 108.4 377.7 ± 91.3 NS
Seattle Heart Failure Model:
Mortality 1 year [%] 6.4 ± 5.7 6.1 ± 4.9 NS
Mortality 2 years [%] 12.2 ± 10.3 11.7 ± 9.3 NS
Mortality 5 years [%] 28.9 ± 20.3 27.9 ± 19.6 NS
Mean life expectancy [years] 11.6 ± 6.5 11.8 ± 6.6 NS
Beta-blocker 22 (100%) 23 (100%) NS
MRA 19 (86.4%) 23 (100%) NS
ACEI 20 (90.9%) 20 (86.9%) NS
ARB 2 (9.1%) 3 (13.04%) NS
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker; BMI — body mass index; BNP — B-type natriuretic 
peptide; CHF — chronic heart failure; COPD — chronic obstructive pulmonary disease; CRT — cardiac resynchronization therapy; eGFR —  
estimated glomerular filtration rate; hs-CRP — high-sensitivity C-reactive protein; LVEF — left ventricular ejection fraction; MRA — mineralo-
corticoid receptor antagonist; NYHA — New York Heart Association; VO2 peak — peak oxygen uptake; 6MWT — six-minute walk test 
after 1-month TMZ treatment (2.5 ± 1.2 mg/L vs. 
6.4 ± 1.2 mg/L). Moreover, in Group 1 there was 
a tendency towards CRP reduction after a 1-month 
period without TMZ (6.4 ± 1.2 mg/L vs. 3.2 ± 1.3 
mg/L, p = 0.071). No effects on CRP were found in 
a 6-month period with TMZ in Group 1 (Fig. 4A, B).
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Mortality and cardiovascular events
No impact on CV mortality of TMZ was ob-
served (odds ratio [OR]: 2.22, 95% confidence 
interval [CI] 0.2–24.5). In addition, TMZ was 
not associated with any significant effects on CV 
events, including CV deaths (OR 0.5, 95% CI 
0.2–1.2; Fig. 4C, D).
Health-related quality of life
Patients in Group 1 had significant deteriora-
tion of quality of life during 6-month TMZ treat-
ment in MacNew Global (5.5 ± 0.2 points vs. 5.1 
± 0.2 points, p < 0.05), MacNew Physical (5.0 ± 
0.2 points vs. 4.6 ± 0.3 points, p < 0.04), MacNew 
Social (5.5 ± 0.2 points vs. 4.9 ± 0.2 points, p < 
0.05), and a tendency towards decreased MacNew 
Emotional (5.9 ± 0.2 points vs. 5.5 ± 0.2 points, 
p = 0.066). Moreover, a significant decrease in 
MacNew Emotional after 6-month treatment with 
standard medical therapy was also noted in Group 2 
(5.7 ± 0.2 points vs. 5.3 ± 0.2 points, p < 0.05; 
Fig. 5A–D).
Analysis of patients who responded with 
LVEF increase after TMZ administration
Patients, who experienced an increase in LVEF 
of at least 5% at any time due to TMZ administration 
in comparison to other patients had the following 
initially: significantly lower BNP level (262.3 ± 
282.7 pg/mL vs. 714.1 ± 653.9 pg/mL; p < 0.05), 
lower 1-year and 2-year mortality (3.6 ± 4.5% vs. 
6.9 ± 5.3%; p < 0.05; and 6.9 ± 7.9% vs. 13.2 ± 
± 9.7%, respectively; p < 0.05), and improved 
predicted life expectancy according to Seattle Heart 
Failure Model (15.5 ± 7.3 years vs. 10.7 ± 6.0 
years; p < 0.05). In addition, patients who had LVEF 
≥ 5% during TMZ treatment in comparison to other 
patients had a tendency towards more frequent oc-
currence of diabetes mellitus or pre-diabetes and 
arterial hypertension (55.6% vs. 22.2%; p = 0.063 
and 77.8% vs. 44.4%, p = 0.077, respectively), 
a tendency towards higher hemoglobin level (15.1 ± 
± 1.1 g/L vs. 13.9 ± 1.6 g/L, p = 0.055), and a ten-
dency towards lower red cell width value (14.2 ± 
























































































Figure 2. Peak oxygen consumption (VO2 peak), VO2 in anaerobic threshold (AT), slope of minute ventilation versus 
carbon dioxide production (VE/VCO2 slope), and six-minute walk test (6MWT) values in both groups at various time 
points.
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Discussion
In this prospective, randomized, open-label 
study the use of TMZ on top of standard medical 
therapy in patients with severe HFrEF did not 
result in any significant improvement in exercise 
capacity, left ventricle contractility and left ven-
tricular diameters, or quality of life. In addition, 
TMZ had no impact on CV events and CV mortality. 
In recent years many studies have shown that 
TMZ has led to improvements in exercise capacity 
in CHF patients. Momen et al. [14] included in their 
study 98 patients with ischemic HFrEF. A signifi-
cantly higher percentage of patients in NYHA class 
I and II was reported in the group that received TMZ 
for 6 months in comparison to patients receiving 
placebo (22% vs. 8%, p = 0.03 for NYHA I class and 
56% vs. 34%, p = 0.01 for NYHA II class, respec-
tively). Moreover, these effects were also reported 
in a study in patients with dilated cardiomyopathy, 
who were randomized to TMZ 20 mg t.i.d. on top of 
standard CHF pharmacotherapy vs. standard CHF 
pharmacotherapy [10]. At 3 months, reduced NYHA 
class (from 2.25 ± 0.5 to 1.85 ± 0.46, p = 0.001) and 
increased 6MWT distance (from 349.8 ± 89.6 m to 
402.1 ± 87.6 m, p = 0.001) were observed in the 
group that received TMZ. In addition, a meta-analysis 
by Gao et al. [6] suggested that TMZ on top of stan-
dard pharmacotherapy resulted in reduced NYHA 
classification (weighted mean difference [WMD] 
0.41, 95% CI 0.51–0.31, p < 0.01) and increased ex-
ercise duration (WMD 30.26 s; 95% CI 8.77–51.75; 
p < 0.01). Our study results with regards to NYHA 
class and 6MWT were partly consistent with those 
of Di Napoli et al. [15], who reported no changes in 
NYHA class after 6-month treatment with TMZ, but 
a significant improvement in exercise capacity in 
patients receiving TMZ was found. Another study 
included 60 patients with dilated cardiomyopathy, 
who were randomized to two groups: one received 
TMZ 35 mg b.i.d. and the other was given placebo. At 
6 months, no significant improvements with regards 
to NYHA class, 6MWT, and VO2 peak in patients 
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Figure 3. Left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), left ventricular end-
-diastolic diameter (LVEDD), and New York Heart Association (NYHA) values in both groups at various time points.
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We found no significant effect of TMZ on 
cardiopulmonary stress testing. There are insuf-
ficient data in the literature concerning the effects 
of TMZ on cardiopulmonary stress testing in CHF 
patients, and 6MWT and total exercise duration 
(TED) were mainly used to assess the impact of 
TMZ on exercise capacity. Our study is therefore 
one of the few observations on TMZ effects with 
regards to cardiopulmonary stress testing. Zhao 
et al. [8] in a meta-analysis of studies including 
subgroup of patients with CHF and coronary artery 
disease reported a significant increase in TED 
(WMD of 50.01 [n = 214, 95% CI 44.77–55.25, 
p < 0.001]). Interestingly, TMZ treatment was also 
associated with significant increase in pVO2 (n = 
= 204, WMD 2.41, 95% CI 1.76–3.06, p < 0.00001), 
METS (n = 611, WMD 1.33, 95% CI 0.38–2.28, 
p = 0.006), and 6-MWT (n = 218, WMD 62.46, 
95% CI 35.86–89.05, p < 0.00001) in patients with 
coronary disease [8]. In another meta-analysis, 
however, no significant effect of TMZ on TED was 
observed [4]. In our study the initially low VO2 
peak values indicate that the study group had an 
advanced CHF. It cannot be excluded, therefore, 
that the lack of anticipated beneficial effects of 
TMZ with regards to cardiopulmonary parameters, 
6MWT distance, and NYHA class may be associ-
ated with the severity of CHF and irreversible 
changes that occurred in myocardium.
Our study revealed a tendency towards 
LVEF increase in patients who received TMZ for 
6 months. Moreover, patients who responded with 
LVEF increase ≥ 5% to TMZ treatment had initially 
lower BNP level, lower 1-year and 2-year mortal-
ity and higher life expectancy according to Seattle 
Heart Failure Model in comparison to patients 
without increase in LVEF ≥ 5% during TMZ admin-
istration. This observation may indicate that there 
is a higher probability of LVEF improvement due 
to TMZ treatment in patients with less advanced 
CHF. In addition, there was a tendency towards 
higher incidence of diabetes or pre-diabetes and 
hypertension in patients with increased LVEF 
≥ 5% in comparison to subjects without increased 
LVEF ≥ 5% on TMZ. The results of studies the 
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Figure 4. B-type natriuretic peptide (BNP), C-reactive protein (CRP) and cardiovascular (CV) events in both groups at 
various time points; ICD — implantable cardioverter defibrillator.
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diabetes are unclear. Thrainsdottir et al. [16] in 
a small group of ischemic CHF patients with diabe-
tes found no effects of TMZ with regards to LVEF, 
while Gunes et al. [17] reported a significant cor-
relation between LVEF rise during TMZ treatment 
and diabetes occurrence (r = 0.524, p < 0.001).
The data concerning the effects of TMZ on left 
ventricular function are conflicting. The majority of 
available studies in CHF reported beneficial effects 
of TMZ on LVEF. Gao et al. [6] observed that TMZ 
treatment resulted in LVEF improvements both in 
ischemic and non-ischemic patients (WMD 7.37%, 
95% CI 6.05–8.7, p < 0.01 and WMD 8.72%, 95% 
CI 5.51–11.92, p < 0.01, respectively). In addition, 
TMZ treatment was associated with significant left 
ventricular end-systolic volume (LVESV) reduction 
(WMD 10.37 mL; 95% CI 15.46–5.29, p < 0.01) 
[6]. In other meta-analysis, a significant increase in 
LVEF (WMD 7.29%, 95% CI 6.49–8.09, p < 0.01), 
reduction of LVESV (WMD –17.09 mL, 95% CI 
–20.15 to –14.04, p < 0.01), and reduction of left 
ventricular end-diastolic volume (WMD –11.24 mL, 
95% CI –14.06 to –8.42, p < 0.01) was found. On 
the other hand, there were also studies that did 
not find any significant effects of TMZ on LVEF in 
CHF patients [13, 15].
We observed no significant effect of TMZ on 
CV events and mortality in patients with HFrEF. 
Meta-analyses and retrospective studies including 
larger numbers of participants provided data on 
the beneficial effect of TMZ in terms of mortality 
reduction. Grajek et al. [7] included 326 patients 
with CHF and reported significant mortality reduc-
tion in patients using TMZ (relative risk [RR] = 
= 0.283, p < 0.0001). Moreover, Fragasso et al. 
[18] analyzed the effect of TMZ on morbidity and 
mortality during 3-year follow-up. This study con-
firmed 11.3% improved global survival (p = 0.015) 
and 8.5% improved survival for CV death (p = 0.05) 
in the TMZ group. Interestingly, the observed rate 
of hospitalization for CV causes was also reduced 
by 10.4% at 5 years (p < 0.0005) with increased 
hospitalization-free survival of 7.8 months [18]. 
Other meta-analysis also corroborated that TMZ 
had a significant positive effect on mortality (RR 
0.29, 95% CI 0.17–0.49, p < 0.00001) and resulted 
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Table 2. Comparison of patients with LVEF ≥ 5% and patients without LVEF ≥ 5% during trimetazidine 
treatment.
Variable DLVEF ≥ 5% (n = 9) DLVEF < 5% (n = 36) P
Age [years] 58.4 ± 9.7 58.4 ± 10.9 NS
Male 9 (100%) 34 (94.4%) NS
CHF duration [years] 3 ± 2.1 3.4 ± 2.6 NS
Coronary artery disease 5 (55.6%) 25 (69.4%) NS
Diabetes or prediabetes 5 (55.6%) 8 (22.2%) 0.063
Hypertension 7 (77.8%) 16 (44.4%) 0.077
Chronic kidney disease 3 (33.3%) 11 (30.6%) NS
COPD 0 5 (13.9%) NS
CRT 1 (11.1%) 9 (25%) NS
NYHA II 6 (66.7%) 23 (63.9%) NS
NYHA III 3 (33.3%) 13 (36.1%) NS
BMI [kg/m2] 27.1 ± 4.1 27.9 ± 4.5 NS
BNP [pg/mL] 262.3 ± 282.7 714.1 ± 653.9 0.025
Hemoglobin [g/L] 15.1 ± 1.1 13.9 ± 1.6 0.055
Red cell width 14.2 ± 1.4 15.4 ± 1.9 0.076
Sodium [mmol/L] 137.2 ± 3.2 138 ± 2.8 NS
hs-CRP [mg/L] 3.1 ± 2.4 3.1 ± 2.2 NS
Creatinine [mg/dL] 1.1 ± 0.2 1.2 ± 0.3 NS
eGFR [mL/kg/1.73 m2] 76.8 ± 18.4 65.8 ± 17.4 NS
Initial HR ≤ 75/min 4 (44.4%) 19 (52.8%) NS
Sinus rhythm 5 (62.5%) 21 (61.8%) NS
Optimal pharmacotherapy 4 (44.4%) 18 (50%) NS
LVEF [%] 23.1 ± 6.6 23.1 ± 6.4 NS
LVEDD [mm] 71.3 ± 4.5 72.6 ± 8.9 NS
LVESD [mm] 61.8 ± 5.9 61.6 ± 9.9 NS
Seattle Heart Failure Model:
Mortality 1 year [%] 3.6 ± 4.5 6.9 ± 5.3 0.03
Mortality 2 years [%] 6.9 ± 7.9 13.2 ± 9.7 0.03
Mortality 5 years [%] 17.9 ± 16.8 31.0 ± 19.7 NS
Mean life expectancy (years) 15.5 ± 7.3 10.7 ± 6.0 0.047
BMI — body mass index; BNP — B-type natriuretic peptide; CHF — chronic heart failure; COPD — chronic obstructive pulmonary disease; 
CRP — C-reactive protein; CRT — cardiac resynchronization therapy; eGFR — estimated glomerular filtration rate; hs-CRP — high-sensitivity 
C-reactive protein; HR — heart rate, LVEDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; LVESD — left 
ventricular end-systolic diameter; NYHA — New York Heart Association
in reduction of CV events and hospitalizations (RR 
0.42, 95% CI 0.30–0.58, p < 0.00001) [6].
We observed no positive effect of TMZ on 
quality of life. The deterioration of quality of life 
in Group 1 after 6-month TMZ treatment may be 
a result of the patients’ disappointment with the 
lack of anticipated beneficial effects of TMZ. Lack 
of improvements in exercise capacity and echocar-
diography may have led to emotional exhaustion. In 
addition, perceived exercise capacity deterioration 
during TMZ treatment may explain the significant 
reduction in the MacNew Physical subscale. The 
majority of studies evaluating TMZ in CHF report-
ed beneficial effects of TMZ on quality of life with 
the use of visual-analogue scale [19–21]. Winter et 
al. [13], on the other hand, reported no beneficial 
effect of TMZ administration on quality of life. 
Limitations of the study
The lack of a double-blind, placebo-controlled 
study and the relatively small sample size may be 
considered as limitations of the study. The exercise 
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capacity assessment, however, was performed by 
using objective methods such as cardiopulmonary 
stress testing or 6MWT, and these results were 
also accompanied by echocardiography and labora-
tory tests. Moreover, the majority of studies that 
focused on TMZ in CHF were open-label and 
largely underpowered. 
In addition, the study was conducted in the 
period 2012–2016. At that time sacubitril/valsartan 
(ARNI) was not available in Poland. Therefore, 
we were not able to test TMZ efficacy in patients 
receiving ARNI. 
The study group was statistically efficient due 
to cross-over methodology. This is one of the few 
prospective, randomized, cross-over evaluations 
of TMZ in advanced HFrEF.   
Conclusions
Trimetazidine on top of standard pharma-
cotherapy in CHF patients, irrespective of CHF 
etiology, did not lead to any beneficial effects on 
CV events, including mortality, it was not associ-
ated with beneficial effect in exercise capacity, and 
it had no positive effect on quality of life in stable 
patients with severe HFrEF. Presumably, patients 
with less advanced stage of CHF may have a bet-
ter response to TMZ, resulting in left ventricle 
contractility improvement. 
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